<div>
<h2>Key Points</h2><ul><li>B Group bought 67,500 shares of Bright Minds Biosciences in the first quarter.</li><li>The quarter-end value of the new stake was $4.93 million.</li><li>Transaction value equates to 4% of B Group, Inc.’s reportable U.S. equity assets</li><li>The new position, while notable, places Bright Minds Biosciences outside the fund’s top five holdings.</li><li>10 stocks we like better than Bright Minds Biosciences ›</li></ul><p>B Group, Inc. disclosed a new stake in <strong>Bright Minds Biosciences</strong> <span class="ticker">(NASDAQ:DRUG)</span> in its May 15, 2026, SEC filing, acquiring 67,500 shares—an estimated $5.43 million trade based on quarterly average pricing.</p><h2 id="what-happened">What happened</h2><p>According to a May 15, 2026, SEC filing, B Group, Inc. initiated a new position in Bright Minds Biosciences, purchasing 67,500 shares. The estimated transaction value is $5.43 million, calculated using the average closing price for the first quarter of 2026. The value of the stake at quarter-end was $4.93 million, a figure that includes both share purchases and movement in the company’s stock price during the period.</p><h2 id="what-else-to-know">What else to know</h2><ul><li>This is a new position for B Group, Inc., representing roughly 4% of reportable AUM as of March 31, 2026.</li><li>Top five holdings after the filing:<ul><li>NASDAQ: ADMA: $28.90 million (21.4% of AUM)</li><li>NASDAQ: PALI: $19.97 million (14.8% of AUM)</li><li>NASDAQ: PRAX: $10.71 million (7.9% of AUM)</li><li>NASDAQ: CLLS: $10.40 million (7.7% of AUM)</li><li>NASDAQ: ZLAB: $8.48 million (6.3% of AUM)</li></ul></li><li>As of Thursday, Bright Minds Biosciences shares were priced at $83.24, up nearly 175% over the past year and well outperforming the S&amp;P 500, which is instead up about 25%.</li></ul><h2 id="company-overview">Company Overview</h2><section><table><tbody><tr><th>Metric</th><th>Value</th></tr><tr><td>Price (as of market close May 14, 2026)</td><td>$83.24</td></tr><tr><td>Market Capitalization</td><td>$815 million</td></tr><tr><td>Net Income (TTM)</td><td>($19.8 million)</td></tr></tbody></table></section><h2 id="company-snapshot">Company Snapshot</h2><ul><li>DRUG develops selective 5-HT receptor agonists targeting epilepsy, pain, and neuropsychiatric disorders, with a portfolio focused on 5-HT2C, 5-HT2A, and 5-HT2C/A compounds.</li><li>The firm operates a pre-clinical biotechnology model, generating value through research collaborations and intellectual property development rather than product sales.</li><li>It targets patients with severe neurological and psychiatric conditions, collaborating with research institutions and healthcare partners to advance clinical applications.</li></ul><p>Bright Minds Biosciences is a pre-clinical biotechnology company specializing in the development of next-generation serotonin-based therapeutics for neurological and neuropsychiatric conditions. The company leverages strategic collaborations with leading medical research institutions to accelerate innovation and expand its intellectual property portfolio. With a focus on high unmet medical needs, Bright Minds aims to establish a competitive edge through targeted drug development and scientific partnerships.</p><h2 id="what-this-transaction-means-for-investors">What this transaction means for investors</h2><p>B Group is stepping into Bright Minds during a massive run higher, suggesting it sees additional upside tied to the company's drug pipeline (given the nature of pre-revenue biotechs). The company's most important asset remains BMB-101, a serotonin receptor agonist being developed for drug-resistant epilepsies. Management has been accelerating development efforts, with research and development spending climbing to C$18.7 million during the first six months of fiscal 2026, up from C$3.6 million a year earlier as clinical and preclinical programs advanced.<br/><br/>Just as important, Bright Minds ended March with roughly C$309.7 million in cash and cash equivalents after completing a January equity offering that raised about $175 million. That gives the company substantial resources to fund development without the near-term financing pressure that often weighs on early-stage biotech firms. For long-term investors, this is still a high-risk, high-reward story. The company has no commercial revenue and remains loss-making. But with a well-funded balance sheet and pipeline progress, there are reasons to be bullish.</p><h2>Should you buy stock in Bright Minds Biosciences right now?</h2>
<p>Before you buy stock in Bright Minds Biosciences, consider this:</p>
<p>The <em>Motley Fool Stock Advisor</em> analyst team just identified what they believe are the <strong>10 best stocks</strong> for investors to buy now… and Bright Minds Biosciences wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.</p>
<p>Consider when <strong>Netflix</strong> made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, <strong>you’d have $475,063</strong>!* Or when <strong>Nvidia</strong> made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, <strong>you’d have $1,369,991</strong>!*</p>
<p>Now, it’s worth noting <em>Stock Advisor’s</em> total average return is 994<span>% — a market-crushing outperformance compared to 207% for the S&amp;P 500. <strong><span>Don't miss the latest top 10 list, available with <em>Stock Advisor</em>, and join an investing community built by individual investors for individual investors.</span></strong></span></p>
<p>See the 10 stocks »</p>
<p style="color: #767676; text-align: left"><em>*Stock Advisor returns as of May 21, 2026. </em></p><p><em>Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Adma Biologics. The Motley Fool has a disclosure policy.</em></p>
<p>The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.</p>
</div>

DRUG

<p>B Group, Inc. acquired 67,500 shares of Bright Minds Biosciences for approximately $5.43 million, representing about 4% of its U.S. equity assets. The investment reflects confidence in Bright Minds' drug pipeline, particularly its lead asset BMB-101 for drug-resistant epilepsy. Despite being a new position and not among B Group's top five holdings, Bright Minds has shown significant stock price growth, up nearly 175% over the past year. The company is well-funded with C$309.7 million in cash, supporting its development efforts.</p>

nasdaq

Bright Minds Biosciences

First Trust NYSE Arca Biotech Index Fd

Adma Biologics

Palisade Bio

Praxis Precision Medicines

Cellectis

Zai Lab

S&P 500

Netflix

NVIDIA

ZAI LAB

NVIDIA Corporation

Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline